Alberta Investment Management Corp Acquires 1,242 Shares of Insulet Co. (NASDAQ:PODD)

Alberta Investment Management Corp grew its holdings in Insulet Co. (NASDAQ:PODD) by 57.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,400 shares of the medical instruments supplier’s stock after acquiring an additional 1,242 shares during the period. Alberta Investment Management Corp’s holdings in Insulet were worth $888,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Blue Trust Inc. raised its holdings in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the period. Venturi Wealth Management LLC increased its position in Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares in the last quarter. TD Private Client Wealth LLC raised its stake in shares of Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 56 shares during the period. Friedenthal Financial purchased a new position in shares of Insulet during the 4th quarter valued at about $57,000. Finally, Versant Capital Management Inc lifted its position in shares of Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after buying an additional 157 shares in the last quarter.

Insider Buying and Selling at Insulet

In other news, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Insulet Trading Down 1.9 %

Shares of PODD opened at $282.80 on Friday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company’s fifty day moving average is $272.98 and its 200 day moving average is $247.11. The stock has a market capitalization of $19.84 billion, a PE ratio of 48.42, a P/E/G ratio of 3.56 and a beta of 1.23.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The firm had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Sell-side analysts expect that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on PODD. Canaccord Genuity Group raised their target price on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday. Raymond James restated an “outperform” rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a research report on Friday. BTIG Research upped their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. TD Cowen raised their price target on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Finally, Morgan Stanley boosted their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $289.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.